Sunshine Lake Pharma Co - Public Comps and Valuation Multiples

Sunshine Lake Pharma Co Overview

About Sunshine Lake Pharma Co

Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.

Founded

2003

HQ

Employees

6.5K+

Website

hecpharm.com

Sectors

Drug Development & Therapeutics

Financials

Last FY Revenue $516M

Last FY EBITDA $49.2M

EV

$4.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sunshine Lake Pharma Co Financials

See Sunshine Lake Pharma Co valuation multiples based on analyst estimates

Sunshine Lake Pharma Co P&L

In the most recent fiscal year, Sunshine Lake Pharma Co reported revenue of $516M and EBITDA of $49.2M.

Sunshine Lake Pharma Co expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sunshine Lake Pharma Co valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$516M	XXX	XXX	XXX
Gross Profit	XXX	$393M	XXX	XXX	XXX
Gross Margin	XXX	76%	XXX	XXX	XXX
EBITDA	XXX	$49.2M	XXX	XXX	XXX
EBITDA Margin	XXX	10%	XXX	XXX	XXX
EBIT	XXX	$60.0M	XXX	XXX	XXX
EBIT Margin	XXX	12%	XXX	XXX	XXX
Net Profit	XXX	$1.2M	XXX	XXX	XXX
Net Margin	XXX	0%	XXX	XXX	XXX
Net Debt	XXX	$332M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sunshine Lake Pharma Co including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Sunshine Lake Pharma Co achieved $516M in revenue and $49.2M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$516M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$393M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	76.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$49.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	9.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$60.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	11.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$1.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	0.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$332M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sunshine Lake Pharma Co

This financial data table provides comprehensive performance metrics for Sunshine Lake Pharma Co, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Sunshine Lake Pharma Co reported $516M in total revenue.
Fiscal year EBITDA was $49.2M.
The company maintained a gross profit margin of 76.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 9.5%.
Net profit margin reached 0.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sunshine Lake Pharma Co. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sunshine Lake Pharma Co Stock Performance

Sunshine Lake Pharma Co has current market cap of HKD 27.5B (or $3.5B), and EV of HKD 31.6B (or $4.1B).

Market Cap Evolution

Sunshine Lake Pharma Co Stock Data

As of October 13, 2025, Sunshine Lake Pharma Co's stock price is HKD 48 (or $6).

See Sunshine Lake Pharma Co trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.1B	$3.5B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sunshine Lake Pharma Co Valuation Multiples

Sunshine Lake Pharma Co's trades at 7.9x EV/Revenue multiple, and 82.4x EV/EBITDA.

See valuation multiples for Sunshine Lake Pharma Co and 15K+ public comps

Sunshine Lake Pharma Co Financial Valuation Multiples

As of October 13, 2025, Sunshine Lake Pharma Co has market cap of $3.5B and EV of $4.1B.

Equity research analysts estimate Sunshine Lake Pharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sunshine Lake Pharma Co's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.5B	XXX	$3.5B	XXX	XXX	XXX
EV (current)	$4.1B	XXX	$4.1B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	7.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	82.4x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	67.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	3012.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-42.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sunshine Lake Pharma Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sunshine Lake Pharma Co Margins & Growth Rates

Sunshine Lake Pharma Co's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Sunshine Lake Pharma Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sunshine Lake Pharma Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sunshine Lake Pharma Co and other 15K+ public comps

Sunshine Lake Pharma Co Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	10%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	19%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	22%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	64%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial